Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST) – A systematic review
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST) – A systematic review. / Brinch, Charlotte Margareta; Aggerholm-Pedersen, Ninna; Hogdall, Estrid; Krarup-Hansen, Anders.
I: Critical Reviews in Oncology/Hematology, Bind 172, 103650, 2022.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Medical oncological treatment for patients with Gastrointestinal Stromal Tumor (GIST) – A systematic review
AU - Brinch, Charlotte Margareta
AU - Aggerholm-Pedersen, Ninna
AU - Hogdall, Estrid
AU - Krarup-Hansen, Anders
N1 - Publisher Copyright: © 2022 The Authors
PY - 2022
Y1 - 2022
N2 - Background: Chemotherapy is ineffective in treating patients with Gastrointestinal Stromal Tumor (GIST). However, several types of tyrosine kinase inhibitors have been investigated since the approval of imatinib in 2001. The purpose of this report was to systematically review studies on the efficacy of neoadjuvant, adjuvant, and lifelong medical oncological treatment of GIST. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed throughout the review process. The protocol was submitted to the International prospective register of systematic reviews database (ID 251724). A systematic literature search was performed, including phase II- and III studies of biological treatment, reporting on treatment effect in patients with GIST. Results: Of 308 identified publications, 42 studies were included in this review. Conclusion: This review gives an overview of the existing evidence for approved lines of oncological treatments and potential alternatives for patients with GIST in the neoadjuvant-, adjuvant- and life-long setting.
AB - Background: Chemotherapy is ineffective in treating patients with Gastrointestinal Stromal Tumor (GIST). However, several types of tyrosine kinase inhibitors have been investigated since the approval of imatinib in 2001. The purpose of this report was to systematically review studies on the efficacy of neoadjuvant, adjuvant, and lifelong medical oncological treatment of GIST. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed throughout the review process. The protocol was submitted to the International prospective register of systematic reviews database (ID 251724). A systematic literature search was performed, including phase II- and III studies of biological treatment, reporting on treatment effect in patients with GIST. Results: Of 308 identified publications, 42 studies were included in this review. Conclusion: This review gives an overview of the existing evidence for approved lines of oncological treatments and potential alternatives for patients with GIST in the neoadjuvant-, adjuvant- and life-long setting.
KW - Adjuvant treatment
KW - Gastrointestinal stromal tumor
KW - Life-long treatment
KW - Medical oncological treatment
KW - Neoadjuvant treatment
KW - Treatment effect
U2 - 10.1016/j.critrevonc.2022.103650
DO - 10.1016/j.critrevonc.2022.103650
M3 - Review
C2 - 35283299
AN - SCOPUS:85126338434
VL - 172
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
M1 - 103650
ER -
ID: 314063358